



# Meeting of the Board of Directors

September 12, 2025  
4:00 – 5:30 PM EST



**LUNG  
CANCER  
CANADA**

AWARENESS. SUPPORT. EDUCATION.

**CANCER  
PULMONAIRE  
CANADA**

SENSIBILISER. SOUTENIR. ÉDIFIER.

# Agenda

- |    |   |         |
|----|---|---------|
| 1. | Confirmation of Quorum, Welcome & President's Remarks – R. Juergens | 4:00 PM |
| 2. | Approval of the minutes of the last Board Meeting – R. Juergens     | 4:03 PM |
| 3. | Business Arising – R. Juergens                                      | 4:05 PM |
| 4. | Consent Agenda – S. Singh   | 4:08 PM |
|    | - Executive Director's Report                                       |         |
| 5. | Finance Report – N. Delisle   | 4:18 PM |
| 6. | 2026 Budget – S. Singh  | 4:28 PM |
| 7. | Discussion Items – All  | 4:38 PM |
|    | I. LCC Strategic Planning   |         |
|    | II. Pan Canada Lung Cancer Action Plan                              |         |
|    | III. Other  |         |
| 8. | Looking Ahead – Key dates   | 5:25 PM |
| 9. | Adjournment – R. Juergens   | 5:30 PM |



LUNG  
CANCER  
CANADA

CANCER  
PULMONAIRE  
CANADA



# **Minutes of the AGM and Last Board Meeting**

## Lung Cancer Canada

### MINUTES of the Annual General Meeting of Lung Cancer Canada (“LCC”) held virtually at 1:00 p.m. (EST) on June 27, 2025

#### PRESENT:

Dr. Stephanie Snow, Maria Amaral, Nicholas Delisle, Dr. Rosalyn Juergens, Scott Lanaway, Elizabeth Moreau, Dr. Paul Wheatley-Price

#### GUESTS:

Shem Singh

#### REGRETS:

Emi Bossio, Dr. Cheryl Ho

#### 1. Welcome

Dr. Stephanie Snow welcomed everyone to the meeting.

#### 2. 2024 Audited Financial Statements

Nicolas Delisle reviewed the financial statements and report of the auditors for the year ending December 31, 2024. Motion: Nicolas Delisle motioned to approve the financial statements together with the report of the Auditor for the year ending December 31, 2024 and Dr. Paul Wheatley-Price seconded. There were no opposed. **Motion Approved**

#### 3. Appointment of Auditors

Nicolas Delisle motioned to appoint the current auditors Pennylegion Chung LLP as auditors of LCC for the fiscal year ending December 31, 2025 and Scott Lanaway seconded. There were no opposed. **Motion Approved**



LUNG  
CANCER  
CANADA

CANCER  
PULMONAIRE  
CANADA

AWARENESS. SUPPORT. EDUCATION.

SENSIBILISER. SOUTENIR. ÉDIFIER.

#### 4. Election of Directors

Dr. Stephanie Snow motioned to approve the current Slate of Directors for 2025-2026 and Dr. Paul Wheatley-Price seconded. There were no opposed. **Motion Approved**

#### 5. LCC Year in Review

Dr. Stephanie Snow reflected on her two terms over the past four years, highlighting major achievements, including the national wide expansion of Evening of Hope, the successful Give a Breath 5K Run and research award, and the Lung Ambitions Awards. Advocacy initiatives, French-language podcasts, updated branding and digital resources strengthened visibility and partnerships, while challenges with drug funding in Quebec continue to require ongoing advocacy.

#### 6. Adjournment

As there was no further business, Dr. Stephanie Snow adjourned the meeting at 1:22 p.m. (EST).

Emi Bossio

Corporate Secretary of the Meeting



LUNG  
CANCER  
CANADA

CANCER  
PULMONAIRE  
CANADA

AWARENESS. SUPPORT. EDUCATION.

SENSIBILISER. SOUTENIR. ÉDIFIER.

## Lung Cancer Canada

### MINUTES of a Meeting of the Directors of Lung Cancer Canada (“LCC”) held virtually at 1:22 p.m. (EST) on June 27, 2025

#### PRESENT:

Dr. Stephanie Snow, Maria Amaral, Nicholas Delisle, Dr. Cheryl Ho, Dr. Rosalyn Juergens, Scott Lanaway, Elizabeth Moreau

#### GUESTS:

Dr. Paul Wheatley-Price, Shem Singh

#### REGRETS:

Emi Bossio, Dr. Kevin Jao

#### 1. Welcome

Dr. Snow welcomed everyone to the June Board meeting.

#### 2. Election of Officers

The motion to approve the Officers for 2025-2026 (Dr. Juergens– President, Maria Amaral – Vice-President, Nicholas Delisle –Treasurer, Emi Bossio – Corporate Secretary) was moved by Dr. Snow and seconded by Nicholas Delisle. All voted in favour and no one opposed. **Motion Approved**

The new President, Dr. Juergens, took over conduct of the meeting.



LUNG  
CANCER  
CANADA

CANCER  
PULMONAIRE  
CANADA

AWARENESS. SUPPORT. EDUCATION.

SENSIBILISER. SOUTENIR. ÉDIFIER.

### 3. Approval of Committees

Lung Cancer Canada is especially pleased that Dr. Geoffrey Liu will take-over from Dr. Juergens to co-chair the Medical Advisory Committee with Dr. Kevin Jao.

The motion to approve the current list of committees was moved by Dr. Juergens and seconded by Dr. Snow. All voted in favour and no one opposed. **Motion Approved**

### 4. Approval of Minutes of the March 21, 2025 Board Meeting

Maria Amaral noted that in item 5 of the March 21, 2025 Board minutes the reference should have been to the LCC "investment advisor" not the LCC "accountant". The motion to approve the Minutes of the March 21, 2025 Board meeting as amended by Ms. Amaral's comment was moved by Dr. Juergens and seconded by Maria Amaral. All voted in favour and no one opposed. **Motion Approved**

### 5. Consent Agenda: Executive Director's Report (Shem Singh)

Mr. Singh expressed appreciation for the Board and all it has done. Notably, LCC has not lost programs despite covid or the economic downturns of the last few years.

(Dr. Ho joins the meeting)

- LCC looks forward to establishing an LCC Research Foundation in the near term.
- Positive discussions have been held with the Lung Ambition Alliance for a continued funding extension for 3 years.
- Give a Breath has raised four times the amount anticipated.
- LCC and its IT provider, IT Pilots, have entered into an annual services agreement which will include a charitable donation aspect to their work for LCC.
- LCC is working with its bank to modernize and streamline accounts which will in turn strengthen LCC's financial processes and controls.
- LLC has successfully entered into a five year lease extension which includes significant leasehold savings to LCC over the term.



LUNG  
CANCER  
CANADA

CANCER  
PULMONAIRE  
CANADA

AWARENESS. SUPPORT. EDUCATION.

SENSIBILISER. SOUTENIR. ÉDIFIER.



## 6. Finance Report (Nicolas Delisle)

Mr. Delisle provided an overview of the finances. 2025 finances are strong and revenues have exceeded budget. LCC may need to consider additional staff, especially considering the exponential growth of Give A Breath. The Motion to approve the Financial Report was moved by Nicholas Delisle and seconded by Dr. Juergens. All voted in favour and no one opposed. **Motion Approved**

## 7. LCC President's Forecast

Dr. Juergens expressed that she felt it was both an honour and a privilege to continue in the footsteps of the past LCC Presidents. Her focus for the future of LCC will be on strengthening all of the tremendous strides LCC has made. Five key areas that she would particularly like to see continue to move forward are:

- 1) access and availability of Lung cancer screening;
- 2) improvement of the speed and access of the diagnostic journey for lung cancer patients;
- 3) working with the federal and provincial governments for more and more timely access to new treatments for those living with lung cancer;
- 4) advocating for more lung cancer research to ensure equitable funding for lung cancer research; and
- 5) broader access to clinical trials and attracting more clinicians and researchers to Canada so Canadians wherever they are located have access to clinical trials.

## 8. Other Business

No other business was raised.

## 9. Adjournment

As there was no further business, the meeting was adjourned at 1:54 p.m. (EST).

Emi Bossio

Corporate Secretary of the Meeting



AWARENESS. SUPPORT. EDUCATION.    SENSIBILISER. SOUTENIR. ÉDQUER.






# **Executive Director's Report** **(For Information Only)**

## Lung Cancer Awareness Month 2025

- Schedule of core activities
  - Faces of Lung Cancer Stakeholder Briefing – November 6
  - Policy Forum – October 7, 28 and November 18
  - Evening of Hope – November 23
  - Lung Cancer Summit (Connect) – Moncton – mid November



*A time to celebrate survivorship and usher in a hopeful future as we come together from coast-to-coast*

## 2025 Evening of Hope – November 23

- Will be held in 6 locations: Vancouver, Calgary, Edmonton, Toronto, Montreal and Halifax.
- In-person Program: 6pm EST – local art project.
- Virtual Program: 7pm EST – video, game, picture mosaic, local art project, online auction, vote on new Evening of Hope name.
  - Vancouver – Jan Pezzaro (venue: TBA)
  - Calgary – Emi Bossio (venue: Wellspring)
  - Edmonton – Tim Monds (venue: Wellspring)
  - Toronto – Bev Moir & Ron Foreman (venue: TBA)
  - Montreal – Stephane Asselin, Eva Dobozy (venue: Cosmodme)
  - Halifax – Jen Roy & MJ Cyr (venue: Citadel Community Centre)




**LCAM**  
*Lung Cancer Awareness Month*

# Evening of Hope

SUNDAY, NOVEMBER 23, 2025

[lungcancercanada.ca/events/evening-of-hope](https://lungcancercanada.ca/events/evening-of-hope)



**LUNG  
CANCER  
CANADA**

**CANCER  
PULMONAIRE  
CANADA**



**LUNG  
CANCER  
CANADA**

**CANCER  
PULMONAIRE  
CANADA**

AWARENESS. SUPPORT. EDUCATION.

SENSIBILISER. SOUTENIR. ÉDIFIER.

## 2025 Faces of Lung Cancer Report Briefing – November 6

Stories that Unite Us. Change that Moves Us.

- The 2025 theme builds on the spirit of community and equity established in 2024 — moving from awareness and access to impact and transformation.
- It highlights the unique power of stories from patients, caregivers, and healthcare professionals not just to inform, but to drive real, systemic change in lung cancer care.
- Each section will explore a system-level challenge through three interwoven lenses: Lived Experience; Clinical and Research Insights; and Action & Advocacy.
- The report aims to identify care gaps, spark new thinking, and accelerate progress toward equitable access to screening, diagnosis, treatment, and support - for everyone, everywhere.
- Logistics and planning for the FOLCR Briefing underway.



## 2025 Lung Cancer Canada Policy Series Bridging the Gap: Precision Medicine in Lung Cancer Diagnosis and Treatment

### **Part 1: Diagnostic Delays and Biomarker Testing**

October 7 – 2:00 – 3:30 PM EST

Highlighting the significance of prompt and coordinated testing to facilitate early access to targeted therapies.

### **Part 2: Treatment Access and Drug Approval Processes**

October 28 – 2:00 – 3:30 PM EST

Examining how delays in drug access affect patient outcomes and exploring the integration of drug approval processes with funding models like value-based healthcare.

### **Part 3: Collaborative Strategies for Reducing Delays**

November 18 – 2:00 – 3:30 PM EST

Emphasizing the need for federal and provincial coordination, as well as collaboration across healthcare providers, patient advocacy groups, and pharmaceutical companies to improve outcomes for lung cancer patients.

A multi-part forum moderated by Dr. Stephanie Snow examining the systemic delays that lung cancer patients face from diagnosis to treatment. Participants recruitment underway.

**It's Time to Get  
Serious About  
Lung Cancer.**



**LUNG  
CANCER  
CANADA**

**CANCER  
PULMONAIRE  
CANADA**

AWARENESS. SUPPORT. EDUCATION.

SENSIBILISER. SOUTENIR. ÉDIFIER.



# Airways of Hope

- Launch of Toronto In-Person Support Group on November 5, 2025
- Support Groups had 5 new participants registered from June to August
- First interviews for Social Worker completed, second interviews to be schedule asap.

Support Groups	Feb	Mar	Apr	May	Jun	Jul	Aug
National	12	11	2	6	5	6	3
Alberta	5	2	4	5	2	4	2
BC	4	5	3	5	5	4	5
Care Partner	2	4	3	3	3	2	6
One-on-One Support							
Social Worker Sessions	13	9	11	4	13	9	11
New Patients	1	1	1		1	1	1
Navigation/Information Support							
Calls	9	8	6	11	9	8	6
Peer-to-Peer							
Requests	2	0	0	2	2	0	0

# Lung Cancer Summit Series

- Rebrand Launch – Transitioning “Regional Lung Cancer Summit” to “Lung Connect” for clearer purpose and stronger connection to patients, caregivers, and clinicians.
- Purpose & Impact – Emphasizes connection, navigation, and actionable local support while boosting appeal for partners and sponsors.

Upcoming schedules:

- Calgary
  - September 26, 2025, 11:00 am – 2:00 pm
- London
  - Late October 2025
- Moncton
  - Mid November 2025
- Kelowna
  - Early December 2025
- Brampton
  - Mid December 2025



## Research

- **Geoffrey Ogram Memorial Research Grant**
  - 2025 application cycle is ongoing and will close on September 30.
  - Will continue to offer up to 2 awards of \$25,000 each.
  - Research committee meeting to be scheduled for late October to early November.
- **Lung Ambition Awards**
  - Contract for the renewal of the Lung Ambition Awards program for the next 3 years has been confirmed and signed by LCC.
  - 2025 winner announcement to take place in early September. Videos and communication materials are being produced by AstraZeneca and will be posted by LCC.
  - The next cycle of the awards is expected to open in November, subject to confirm with the AZ/LAA team.
- **Give A Breath 5K Research Program**
  - 2025 application cycle is ongoing and will close September 30.
  - Will continue to offer up to 2 awards of \$25,000 each.



## Lung Cancer Voices Podcast Series

- 12 English podcasts with Dr. Paul Wheatley-Price have been produced and launched, with new episodes continuing to be released about every three weeks. Continuous discussions on potential topics will be conducted.
- 2 French podcast series with Dr. Nathalie Daaboul were produced, 2 more episodes recordings with guests are scheduled for September. 1 episode recorded from 2024 is ready for posting.



**LUNG  
CANCER  
CANADA**

**CANCER  
PULMONAIRE  
CANADA**

AWARENESS. SUPPORT. EDUCATION. SENSIBILISER. SOUTENIR. ÉDIFIER.

## HTA Submissions

- Canada Drug Agency CDA - 1 file
  - Lurbinectedin - patient input being written by LHF with interviews and majority of info gathering done by LCC. MAC input confirmed to be done by Dr. Geoffrey Liu.
- INESSS - 2 files
  - Lorlatinib - to be written by Dr. Nicolas Marcoux, pt already completed previously, due on October 6.
  - Osimertinib + chemo FLAURA2 – MAC and patients done, due on October 13.
- LCC has engaged and participated in the recent CDA webinars regarding biomarker testing, evolving patient and clinician inputs. Feedback has been submitted to CDA for evolving the patient input, and clinician input feedback is being compiled for submission with MAC, due on September 15.
- CCRAN is leading a collective patient submission for the CDA biomarker testing framework, and LCC is collaborating with our input (from MAC and patient voice) sent and to be incorporated within the group submission.



## Lung Nurses Network

- Formed to create a community of practice for RNs caring for those living with lung cancer and ensure the promotion of LCC's materials and support programs.
- Current Members: 8. Provincial breakdown: BC 1, SK 2, ON 3, NS 1.
- Planned Activities
  - September
    - Email correspondence with current members to establish priority of proposed activities.
    - Targeted promotion through established contacts recruit at least one member from AB, MN, QC, NB, and if possible, NL and PEI.
  - October - Organize group meeting/outing at CANO 2025.
  - November - Support members promotion of LCAM.
  - December - Establish schedule of activities for 2026.
  - Ongoing
    - Update LNN webpage with resources shared by nurses for nurses.
    - Continued recruitment.



**Are you a nurse with a vested interest in the lung cancer field?**

Welcome to the Lung Nurses Network, a dedicated community within Lung Cancer Canada committed to supporting and empowering lung cancer nurses across the country.

This network is a space for you to connect, educate, and grow as we work together to provide the highest standard of care for those impacted by lung cancer



## Medical Advisory Committee

- MAC Chair Transition Meeting – Discussion focused on strengthening the Medical Advisory Committee's (MAC) role, identity, and alignment with LCC's mission.
- Vision – Position MAC as a leadership engine within LCC, driving evidence-based, nationally relevant, and equitable solutions.
- Priorities – Maintain Health Technology Assessment (HTA) engagement as a key priority, while increasing MAC's visibility and influence in national initiatives like the Pan-Canadian Lung Cancer Action Plan (LCAP); enhance connection with the Board and leadership.
- Engagement – Explore expectations, accountability, and opportunities for members to participate in public-facing advocacy, reports, and campaigns.
- Structure – Consider sub-committees to harness members' expertise and provide targeted, timely insight on critical issues.

## Industry Funding Sponsorships

- As of August 26
  - Confirmed sponsorships: total \$635,825
    - Core Programs - \$345,000
    - Public Affairs - \$175,825
    - Evening of Hope - \$50,000
    - Awareness Campaign - \$65,000
  - Awaiting decision: 2 companies
    - Pfizer - \$25,000 - Public Affairs
    - Boehringer Ingelheim - \$50,000 - Awareness Campaign

## Strategic Planning

### A Roadmap for LCC's Next 3 Years

- A validation and refresh of LCC's current strategic plan to reflect significant organizational growth, new external realities, and strategic opportunities (including the Pan-Canadian Lung Cancer Action Plan), while aligning with the launch of the LCC Research Foundation, and LCC's newly-established policy priorities.
- Timeline and project plan currently in development.

### Guiding Principles

- Patient and caregiver support remains central — the core mission is non-negotiable.
- Build on existing strengths while sharpening LCC's unique value proposition in a competitive space.
- Integrate the LCC Research Foundation and LCC's policy work as major strategic drivers.
- Accelerated process — compressed timeline to maintain momentum and align with key events.
- Evidence-informed and data-driven decision-making.
- Stakeholder engagement for validation rather than prolonged exploratory phases.
- Outcome: Action-oriented plan with measurable goals, milestones, and clear accountability.





## LCC Research Foundation


- Lung Cancer Canada is continuing to develop the LCC Research Foundation, an internal initiative that will focus on funding external, evidence-based research supporting early detection, treatment access, and health equity for those affected by lung cancer.
- Since August, we have launched the initial planning phase and held a kickoff meeting with the working group to begin shaping the Foundation's structure, governance, and priorities.
- Engaged legal counsel to review our corporate objects and confirm the pathway for establishing the Foundation, ensuring it aligns with our existing framework.
- Initiated external consultations with other organizations and experts to gather best practices and inform our approach.
- The target soft launch date remains January 1, 2026, with the hard launch to coincide with the refreshed Strategic Review/Plan announcement (April 2026). We will continue to update as key milestones are achieved.

## Office Lease Extension

- LCC has renewed its lease for 5 years (November 1, 2025 – October 31, 2030)
- Renewal secured at a comparable rate to our previous lease, while also representing a favorable and competitive rate compared to similar downtown office spaces.
- Successfully negotiated one-month of free base rent in Year 3 of the term.
- Renewal ensures operational continuity, stability, and avoids disruption or added costs of relocation.

## RBC PayEdge Platform

- The integration and setup of RBC PayEdge are actively progressing to modernize our accounts payable process.
- We remain on track to complete onboarding, authentication, and testing by the end of Q3.
- This implementation will provide secure, flexible payment options while reducing processing time, improving oversight, and eliminating manual cheque handling.





# Finance Report

Cash balance on September 9, 2025: \$784,872.89

GIC 1 \$500,000.00 1 yr NR GIC at 3.00% mat Jan 17, 2026

Investment account market value at:

July 31, 2025	\$1,484,573.41
June 30, 2025	\$1,477,796.98
May 31, 2025	\$1,444,433.49
April 30, 2025	\$1,398,685.68
March 31, 2025	\$1,416,167.51
February 28, 2025	\$1,423,201.58
January 31, 2025	\$1,428,431.33
December 31, 2025	\$1,405,223.95
November 30, 2024	\$1,458,652.59
October 31, 2024	\$1,429,399.38
September 30, 2024	\$1,443,660.80
August 31, 2024	\$1,408,020.84
July 31, 2024	\$1,395,672.61
June 30, 2024	\$1,350,441.74
May 31, 2024	\$1,354,987.85
April 30, 2024	\$1,321,397.61
March 31, 2024	\$1,339,919.70
February 29, 2024	\$1,313,423.36
January 31, 2024	\$1,328,624.73



**LUNG  
CANCER  
CANADA**

**CANCER  
PULMONAIRE  
CANADA**

AWARENESS. SUPPORT. EDUCATION.

SENSIBILISER. SOUTENIR. ÉDUQUER.



8:28 PM  
09/05/25  
Accrual Basis

## Lung Cancer Canada Profit & Loss Budget Performance August 2025

	Aug 25	Budget	\$ Over Budget	Jan - Aug 25	YTD Budget	\$ Over Budget	Annual Budget
<b>Ordinary Income/Expense</b>							
<b>Income</b>							
Total 4000 · Grants - Corporate	0.00	13,000.00	-13,000.00	485,825.00	297,000.00	188,825.00	610,000.00
4050 · Foundation Grants	0.00	500.00	-500.00	3,000.00	3,000.00	0.00	5,000.00
Total 4100 · Donations - General	9,172.18	17,000.00	-7,827.82	74,142.63	122,000.00	-47,857.37	185,000.00
Total 4300 · Research Funds	0.00	0.00	0.00	171,373.35	130,000.00	41,373.35	180,000.00
4455 · Program Rev. - Patient Guides	0.00	1,000.00	-1,000.00	0.00	7,000.00	-7,000.00	10,000.00
Total 4460 · Events	0.00	8,300.00	-8,300.00	201,235.64	161,600.00	39,635.64	196,000.00
Total 4500 · Other Income	0.00	0.00	0.00	96,064.22	0.00	96,064.22	
<b>Total Income</b>	<b>9,172.18</b>	<b>39,800.00</b>	<b>-30,627.82</b>	<b>1,031,640.84</b>	<b>720,600.00</b>	<b>311,040.84</b>	<b>1,186,000.00</b>
<b>Expense</b>							
Total 5000 · Administration	6,915.64	25,714.00	18,798.36	168,438.27	202,328.00	33,889.73	290,700.00
Total 5100 · Program	63,114.00	65,253.00	2,139.00	433,971.23	554,648.00	120,676.77	810,350.00
Total 5200 · Fundraising & Communications	1,749.00	4,578.00	2,829.00	10,912.41	35,646.00	24,733.59	53,958.00
Total 5300 · Research	0.00	0.00	0.00	164,640.13	153,336.00	-11,304.13	205,000.00
<b>Total Expense</b>	<b>71,778.64</b>	<b>95,545.00</b>	<b>-23,766.36</b>	<b>777,962.04</b>	<b>945,958.00</b>	<b>-167,995.96</b>	<b>1,360,008.00</b>
<b>Net Ordinary Income</b>	<b>-62,606.46</b>	<b>-55,745.00</b>	<b>-6,861.46</b>	<b>253,678.80</b>	<b>-225,358.00</b>	<b>479,036.80</b>	<b>-174,008.00</b>
<b>Net Income</b>	<b>-62,606.46</b>	<b>-55,745.00</b>	<b>-6,861.46</b>	<b>253,678.80</b>	<b>-225,358.00</b>	<b>479,036.80</b>	<b>-174,008.00</b>



**LUNG  
CANCER  
CANADA**

**CANCER  
PULMONAIRE  
CANADA**

AWARENESS. SUPPORT. EDUCATION.

SENSIBILISER. SOUTENIR. ÉDIFIER.

8:30 PM  
09/05/25  
Accrual Basis

**Lung Cancer Canada**  
**Balance Sheet**  
As of August 31, 2025

	Aug 31, 25		
<b>ASSETS</b>			
Current Assets			
Chequing/Savings			
Total 1001 · Bank Accounts	1,221,375.47		
Total 1002 · Investment Accounts	1,484,573.41		
Total Chequing/Savings	2,705,948.88		
Other Current Assets			
1110 · GST Rebate (receivable)	39,178.14		
1200 · Rent Deposit	5,753.20		
Total Other Current Assets	44,931.34		
Total Current Assets	2,750,880.22		
<b>TOTAL ASSETS</b>	<b>2,750,880.22</b>		
<b>LIABILITIES &amp; EQUITY</b>			
Liabilities			
Current Liabilities			
20000 · Accounts Payable	1,108.20		
2162 · RBC VISA 4492	5,156.38		
2230 · Deferred Contributions			
2235 · General Deferred Contributions	96,765.33	====>	
2240 · Deferred Contribution - GOMRF	139,957.73		
2245 · Lindsay Gembicki Memorial Fund	21,756.50		
2246 · Deferred Kayla's Angel Fund	24,833.81		
2247 · Deferred Donation for Research	279,630.78		
2248 · Deferred Elizabeth Dessureault	16,555.17		
2251 · Deferred LAA Marketing Fund	3,004.80		
2253 · Deferred GaB Research	57,801.50		
2260 · Deferred MikeBossy MemorialFund	46,434.20		
Total 2230 · Deferred Contributions	686,739.82		
Total Current Liabilities	693,004.40		
Total Liabilities	693,004.40		
Equity			
32000 · Retained Earnings	1,804,197.02		
Net Income	253,678.80		
Total Equity	2,057,875.82		
<b>TOTAL LIABILITIES &amp; EQUITY</b>	<b>2,750,880.22</b>		

2235 · General Deferred Contributions	
Roche - Digital Patient Guide	22,771.80
Jazz Pharma Canada Inc.	30,706.62
Amgen (HopeAmy)	22,926.91
Convoy of Hope	20,360.00
<b>Total 2235 · General Deferred Contributions</b>	<b>96,765.33</b>

**\*NOTE – As LCC has grown tremendously (note the significant number of new initiatives, new systems, volume of transactions/contracts, implementation of risk management etc, our reporting templates require updating and will be reflected in our December reports and draft Budget for 2026)**

## REVENUES

Over budget \$311K with major variances attributable as follows:

- 189K over budget on Corporate Contributions \* Policy Forum and Awareness Campaigns also included here
- 41K over budget on Give a Breath Research fund
- 40K over budget on GaB Donation, Registration and Sponsorship
- 48K under budget on General Donation
- 7K under budget on Patient Guides
- 96K investment income (Dividend, Interest and Unrealized Gain) that is not budgeted.

## EXPENSES

Under budget \$169K with major variances attributable as follows:

Administration (includes all office and non-program, non-fundraising expenses)

- Under budget \$34K: savings mainly on IT audit, web hosting, meeting expenses, and rent.

Program (includes Education, Awareness and Advocacy initiatives)

- Under budget \$121K: 50K under budget on program salaries, 37K under budget on Airways of Hope; 16K over budget on Regional Patient Summit; 17K under budget on Policy Forum; 33K under budget on other programs..

Fundraising & Communications (includes Charity Runs, Evening of Hope and Merchandise Sales)

- Under budget \$25K: 10K under budget on Website Translation; 8K under budget on Marketing; 7K under budget on other programs.

Research (includes GaB, Pfizer, Lung Ambition, Mike Bossy Memorial Fund, GOMRG Research Fund and LCC Research grant)

- Over budget \$11K: \$25K under budget on GaB research awards (not issued yet), 36K over budgeted on Mike Bossy Memorial Fund



**LUNG  
CANCER  
CANADA**

**CANCER  
PULMONAIRE  
CANADA**



# Looking Ahead – Key Dates



## Dates for Upcoming Board Meetings

LCC Executive Committee  
Board Meeting

December 2025 (TBD)  
December 12, 2025

LCC Executive Committee  
Board Meeting

April 2026 (TBD)  
April 9 or 10, 2026 (To be Finalized)

LCC Executive Committee  
Board Meeting

June 2026 (TBD)  
June 11 or 23, 2026 (To be Finalized)



LUNG  
CANCER  
CANADA

CANCER  
PULMONAIRE  
CANADA



**LUNG  
CANCER  
CANADA**

AWARENESS. SUPPORT. EDUCATION.

**CANCER  
PULMONAIRE  
CANADA**

SENSIBILISER. SOUTENIR. ÉDIFIER.